Nektar Therapeutics (NKTR) Cost of Revenue (2010 - 2026)

Nektar Therapeutics has reported Cost of Revenue for 17 years, with the latest figure at $7.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 55.38% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at -$30.2 million (down 175.37% YoY), and the FY2024 full-year result was $42.0 million, up 24.52% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.7 million, up from -$37.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $17.3 million in Q1 2025, with the low at -$37.9 million in Q4 2025.
• Average Cost of Revenue over 5 years is $5.1 million, with a median of $7.1 million recorded in 2023.
• Year-over-year, Cost of Revenue jumped 150.02% in 2023 and sank 540.22% in 2025.
• Tracing NKTR's Cost of Revenue over 5 years: stood at $6.2 million in 2022, then increased by 16.85% to $7.3 million in 2023, then grew by 18.15% to $8.6 million in 2024, then slumped by 540.22% to -$37.9 million in 2025, then soared by 120.33% to $7.7 million in 2026.
• The last three Cost of Revenue figures came in at $7.7 million (Q1 2026), -$37.9 million (Q4 2025), and $17.3 million (Q1 2025), per Business Quant data.

Peer Comparison